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Objectives: Elevated concentrations of oxidised low density lipoproteins (OxLDL) are associated with accelerated 
atherogenesis. The aim of our study was to determine the effect of OxLDL on the proliferation rate and platelet derived 
growth factor (PDGF) AA production on aortic smooth muscle cells. High density lipoproteins (HDL), which are known 
to have a protective ffect against atherosclerosis, were used as control. 
Materials and methods: Bovine aortic smooth muscle cells were grown in presence of increased concentrations of 
OxLDL and HDL and in presence of control medium culture (DMEM). Proliferation rate was assessed by aH-thymidine 
uptake. PDGF AA production was determined by ELISA and Western Blot Analysis. 
Results: OxLDL increased the proliferation rate of aortic smooth muscle cells as compared to DMEM and HDL (p<O.O01). 
The mitogenic activity of OxLDL on smooth muscle cells was reduced adding anti-PDGF AA antibodies (p<O.O01). 
PDGF AA production by aortic smooth muscle cells was increased after exposure to OxLDL as compared to DMEM 
(p<O.O01). HDL significantly reduced the production of PDGF AA by aortic smooth muscle cells (p<O.O01). 
Conclusions: Part of the atherogenic effect of OxLDL is mediated through the autocrine production of PDGF AA from 
aortic smooth muscle cells. 
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Introduction 
Atherosclerosis is the principal cause of death in Eur- 
ope. Clinical and experimental studies have clearly 
established that elevated concentrations of low density 
lipoproteins (LDL) are associated with accelerated 
atherogenesis and that oxidative modification of LDL 
to oxidised OxLDL enhances its atherogenicity. 1'2 
OxLDL has been found in atherosclerotic lesions from 
human and rabbits suggesting the possible modifica- 
tions of LDL to OxLDL in vivo. 3'4 In vitro, conversion 
of LDL to OxLDL occurs upon incubation of LDL 
with either endothelial cells (EC), smooth muscle cells 
(SMC) and macrophages or in presence of metal ions 
such as Cu++. 5 
OxLDL exhibits awide variety of potentially athero- 
genic properties in vitro, including stimulation of pro- 
liferation, migration and adhesion of EC, SMC and 
monocytes. 1'6-90xLDL enhances intracellular f ee cal- 
cium in vascular SMC ~° and also inhibits the endo- 
thelial cell-dependent release of prostacyclin (PGI2)) 1 
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High concentrations of high density lipoproteins 
(HDL), on the contrary, are known to decrease the risk 
of coronary artery disease xerting a protective role 
in the development of atherosclerosis. 12-15 SMC pro- 
liferation plays a key role in the development of the 
early atherosclerotic plaque. 16 However, the mech- 
anism responsible for SMC proliferation is not clear. 
Platelet derived growth factor (PDGF) is a potent 
mitogen for SMC. PDGF was originally identified from 
human platelets, but other types of cells were found 
to be able to release PDGF-like molecules, including 
EC and SMC.  17 Particularly, SMC produce the PDGF 
AA isoform. 18'19 We hypothesised that accumulation 
of OxLDL in the arterial wall might lead to SMC 
proliferation through induction of PDGF AA pro- 
duction by the SMC themselves. The aim of our study 
was to assess the influence of OxLDL on the production 
of PDGF AA by aortic SMC. 
Material and Methods 
Cell culture 
Smooth muscle cells were obtained from bovine thor- 
acic aortas by collagenase digestion according to a 
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method previously described. 2°The cells were seeded 
into 12 well culture plates (Falcon Plastics, Oxnard CA, 
U.S.A.) in a medium consisting of Dulbecco Modified 
Eagle Medium (DMEM) supplemented with 10% foetal 
calf serum (FCS) and antibiotics (penicillin 100 IU/ml, 
streptomycin 100 Bg/ml, gentamycin 200 ~tg/ml). The 
cultures were kept at 37 °C in an atmosphere of 5% 
CO2. At cell confluence the medium was changed with 
DMEM without FCS (serum-free medium). The cells 
were then kept under standard culture condition for 
24 h. Thereafter, serum-free medium was changed and 
human LDL (Sigma Chemical Co., St. Louis MO, 
U.S.A.) or human HDL (Sigma) were added. In- 
cubation of native LDL with SMC for at least 24 h 
determines LDL oxidation as previously demonstrated 
by thiobarbituric acid reactivity. 5'21 After 72 h of cell 
culture aliquots of conditioned medium were re- 
moved, centrifuged for 5 min at 15 000 rpm and stored 
at -80  °C. Cell viability count was assessed with the 
Trypan blue (Sigma) dye exclusion method. 
PDGF AA assay in the conditioned media 
The presence of PDGF AA molecule in the serum free 
conditioned media from SMC stimulated with OxLDL 
and HDL was determined by an inhibition antibody- 
binding assay. Dilutions of polyclonal rabbit anti- 
PDGF AA antibody (Genzyme Diagnostic, Cambridge, 
MA, U.S.A.) were incubated with aliquots of con- 
ditioned media in 500 Ixl tubes precoated with Phos- 
phate Buffer Saline-gelatin 2% (PBS-gelatin 2%). After 
20 h of incubation at 4 °C, Staphylococcus aureus protein- 
A was added and the immunoaggregates were re- 
moved by centrifugation. 
The residual antibody-binding activity in the super- 
natant was measured by ELISA. Briefly, plastic wells 
(96 wells, Falcon Plastics) were coated with human 
recombinant PDGF AA (Boehringer Mannheim) 
(10 ng/well) for 8 h at 4 °C. Plates were then washed 
twice with PBS and saturated with PBS-gelatin 2% for 
2 h at 37 °C. Washed cells were then filled with 50 ~tl 
per well of supernatant obtained after immuno- 
precipitation. After 2 h of incubation at 37 °C the wells 
were washed with PBS-gelatin 0.2%. Peroxidase 
labeled goat anti-rabbit immunoglobulin antibody 
(Sigma) was added. After 60 min of incubation at 37 °C 
the plates were washed three times in PBS-gelatin 
0.2% and once in distilled water. O-phenylendiamine 
dihydrochloride (0.4mg/ml) (Sigma) was added as 
substrate for the enzyme. Bound specific antibody was 
quantitatively measured by optical density reading at 
492nm with a spectrophotometer (Beckman In- 
struments, Inc., Palo Alto, CA, U.S.A.). The amount 
of PDGF AA was determined by a reference curve 
obtained using known quantities of human re- 
combinant PDGF AA. We used anti-PDGF AA anti- 
body as positive control and antibody without 
specificity as negative control. The polyclonal anti- 
PDGF AA antibody does not cross-react with PDGF 
BB and only partially with PDGF AB. The amount of 
PDGF AA released was expressed as function of the 
number of SMC. 
Mitogenic activity of OxLDL 
SMC were seeded into 96-well culture plates (Falcon) 
at a concentration of 4 x 104 cells/ml in DMEM 0.1% 
FCS. LDL were added at various concentrations 
(0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml) when 
SMC were seeded into wells (200 ~d/well). Positive 
control received human recombinant PDGF (20ng/ 
ml) and negative control serum-free DMEM. After 54 h 
of incubation at 37 °C in an atmosphere of 5% CO2, 
tritiated thymidine was added (0.5 ~tCi/well) for 18 h. 
The cells were then collected on Skatron filters (Skatron 
Instruments, Sterling, Va, U.S.A.) for radioactivity 
determination in a LKB (LKB Instruments Inc., 
Gaithersburg, Md, U.S.A.) scintillation counter. 
Similar experiments were performed adding HDL 
at various concentrations (0.1mg/ml, 0.2mg/ml, 
0.3mg/ml, 0.4mg/ml) on SMC seeded into wells 
(200 tl/well). Tritiated thymidine was added (0.5 ~tCi/ 
well) for 18 h and the radioactivity was measured. 
Mitogenic activity reduction by anti-PDGF AA antibody 
Measurements of the ability of OxLDL to stimulate 
DNA synthesis of SMC was repeated in the presence 
of an excess of polyclonal antibody to PDGF-AA (4 Ixg/ 
ml) (Genzyme) (50% v/v). Tritiated thymidine was 
added and SMC cultures were incubated under stand- 
ard culture condition for 18 h. After further processing, 
the radioactivity was measured. 
Western blot analysis 
SMC were grown on T25 culture flask (Falcon Plastics) 
in complete medium and at cell confluence the medium 
was changed with DMEM without FCS. After 24 h the 
medium was changed again and LDL (0.2 mg/ml) or 
HDL (0.2 mg/ml) were added. After 72 h the SMC 
were trypsinised, the cell suspension washed twice 
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with cold PBS and lysed with a ice-cold lysis buffer 
[50 mM HEPES (pH 7.0), 1% NP-40, 100 ~tg/ml PMSF 
(phenylmethyl-sulfonyl fluoride) (freshly prepared)]. 
After 20 min of incubation on ice the lysate was cent- 
rifuged at 12 000 rpm for 2 min in a microfuge. The 
supernatant was saved and the protein concentration 
determined spectrophotometrically at As95 with the 
Bradford reagent (Sigma). The samples, containing 
identical amounts of protein, were suspended in 
sample buffer not reducing (10% glycerol, 2% Sodium 
Dodecyl Sulfate [SDS], 0.25 tool Tris pH 6.8, 0.001% 
bromophenol blue and 0.046% iodacetam), boiled for 
3 to 5 min and centrifuged at 10 000 rpm for 10 rain. 
The samples were then separated by 15% SDS-poly- 
acrylamide gel electrophoresis under non-reducing 
conditions. The proteins were blotted onto nitro- 
cellulose overnight. All of the following incubations 
were carried out at room temperature. Non-specific 
binding was blocked by 0.2% casein for I h, followed 
by antibody to PDGF AA (Genzyme) (4 Bg/ml) for 
about i h. After rinses, the filter was probed for i h with 
1:10 000 dilution of anti-rabbit IgG antibody alkaline 
phosphatase conjugate (Tropix Inc., Bedford, MA, 
U.S.A.). After rinses, the filter was immersed in chemi- 
luminescent substrate (Tropix) and exposed to Kodak 
XAR X-ray film for 20 min. Human recombinant PDGF 
AA (10 ng) (Boehringer Mannheim) was used as posi- 
tive control. 
Statistical nalysis 
Analysis of variance (ANOVA) with Bonferroni cor- 
rection was used for statistical analysis. Differences 
were considered at the level of p<0.05. 
Results 
PDGF AA assay in the conditioned media 
Smooth muscle cell cultures were stimulated with LDL 
and HDL in a serum-free medium at concentrations 
from 0.1 mg/ml to 0.4 mg/ml. Incubation of LDL with 
SMC for at least 24 h determines LDL oxidation. LDL 
were, then, considered OxLDL. After 72 h of cell cul- 
ture aliquots of conditioned medium were collected 
and SMC viability count was determined by Trypan 
blue dye exclusion method. The presence of PDGF 
AA in these conditioned media was assayed by an 
inhibition antibody-binding assay using specific anti- 
body. The amount of PDGF AA, expressed in ng/ml, 
Table 1. Release of PDGF AA by SMC stimulated with LDL and 
HDL (ng/10 6cells). 
LDL and HDL LDL HDL 
concentrations 
0 mg/ml 43 ± 7.2* 43 ± 7.2* 
0.1 mg/ml 52 ±4.7** 10 ± 1.0 *~ 
0.2 mg/ml 64 ± 1.5"* 10 ± 0.8 ~* 
0.3 mg/ml 71 ± 8.0*  7 ± 0.7"* 
0.4 mg/ml 86 ± 11.6"* 5 ± 0.2 ~ ~ 
*The value represents the mean ± s.D. of 20 separate experiments. 
**The value represents the mean ± s.D. of 6 separate experiments. 
were determined with a reference curve obtained using 
known quantities of human recombinant PDGF AA. 
Smooth muscle cells stimulated with OxLDL re- 
leased more PDGF AA (p<0.001) than controls HDL 
and DMEM. Smooth muscle cells stimulated with HDL 
released less PDGF AA (p<0.001) than control DMEM. 
Table 1 shows the amount of PDGF AA released by 
SMC expressed in ng/106 cells. PDGF AA release 
augmented with the increase of OxLDL concentration 
and decreased with the increase of HDL concentration. 
Mitogenic activity of OxLDL 
Addition of LDL at various concentrations (from 
0.1 mg/ml to 0.4 mg/ml) to the medium of SMC cul- 
tures determined a statistically significant increase in 
tritiated thymidine uptake as compared to negative 
control DMEM (p<0.05 for LDL 0.1 mg/ml; p<0.01 
for LDL 0.2 mg/ml; p<0.001 for LDL 0.3 mg/ml and 
0.4 mg/ml) (Fig. la). 
Addition of HDL at various concentrations (from 
0.1 mg/ml to 0.4 mg/ml) to the medium of SMC cul- 
tures determined a slight increase in tritiated thy- 
midine uptake as compared to negative control DMEM 
(Fig. lb), but this difference was not statistically sig- 
nificant. 
Mitogenic activity reduction by anti-PDGF AA antibody 
Addition of polyclonal anti-PDGF AA antibody to 
the medium of SMC cultures exposed to LDL at the  
concentration f 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml and 
0.4mg/ml decreased the tritiated thymidine uptake 
by 5% (p>0.05), 22% (p<0.001), 24% (p<0.001) and 26% 
(p<0.001) respectively. Addition of polyclonal anti- 
PDGF AA antibody to the medium of SMC cultures 
exposed to HDL at the concentration of0.2 mg/ml did 
not influence the tritiated thymidine uptake (Fig. 2). 
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Fig. 1. Addition of LDL at various concentrations (from 0.1mg/ 
ml to 0.4mg/ml) to the medium of SMC cultures determined a
statistically significant increase in tritiated thymidine uptake as 
compared to negative control (p<0.05 for LDL 0.1mg/ml; p<0.01 
for LDL 0.2mg/ml; p<0.001 for LDL 0.3mg/ml and 0.4mg/ml) 
(A). Addition of HDL at various concentrations (from 0.1 mg/mi to 
0.4 mg/mI) to the medium of SMC cultures determined a slight, 
not statistically significant increase in tritiated thymidine uptake as 
compared to negative control (B). Each column represents he mean 
value --S.D. of three separate xperiments performed in triplicate. 
DMEM: negative control; hrPDGF: positive control. 
Western Blot Analysis 
To demonstrate hat PDGF AA is produced by SMC 
in response to OxLDL, we examined the appearance 
of PDGF AA in cell lysates. Lysates obtained from 
SMC which had been stimulated by LDL (0.2 mg/ 
ml) and HDL (0.2 mg/ml) for 72 h were subjected to 
Western blotting and probed with polyclonal anti~ 
PDGF AA antibody. As shown in Fig. 3 PDGF AA 
was significantly more abundant in lysate obtained 
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Fig. 2. Addition of polyclonal anti-PDGF AA antibody to the medium 
of SMC cultures exposed to LDL at the concentration of 0.1 rag/ 
ml, 0.2 mg/ml, 0,3mg/ml and 0.4mg/ml decreased the tritiated 
thymidine uptake by 5% (p>0.05), 22% (p<0.001), 24% (p<0.001) and 
26% (p<0.001), respectively. 
Addition of polyclonal anti-PDGF AA antibody to the medium 
of SMC cultures exposed to HDL at the concentration of 0.2 rag/ 
ml did not influence tritiated thymidine uptake• DMEM columns 
represent medium of SMC cultures not exposed to LDL or HDL, in 
which antibody to PDGF AA has been added. Each column rep- 
resents the mean value --S.D. of three separate xperiments per- 
formed in triplicate (ll) w/0 anti-PDGF AA; ([]) with anti-PDGF 
AA. 
A B C D 
PDGF AA -+ 
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Fig. 3. Western blot analysis: PDGF AA was more abundant in 
lysate obtained from SMC stimulated with LDL (0.2 mg/ml) (lane 
B) than in lysate obtained from SMC stimulated with HDL (0.2 rag/ 
ml) (lane C) or unstimulated (lane D). To confirm the identity of 
the band as PDGF AA, a human recombinant PDGF AA (10 ng) 
was also electrophoresed as a positive control (lane A). 
from SMC stimulated with OxLDL than in lysate 
obtained from SMC stimulated with HDL or un- 
stimulated. 
Discussion 
The les ions of a therosc le ros i s  are character i sed  by  
focal  areas of l ip id  accumulat ion  and  in t ima l  SMC 
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proliferation within the arterial wall. Increased plasma 
LDL results in the formation of macrophage-derived 
"foam" cells. These events could provide a mechanism 
for increased growth factor production. 22
Several in vitro biologic consequences of OxLDL 
have been demonstrated including, increased mono- 
cyte adhesion to EC,  23-26 monocyte chemotaxis, 27 
decreased macrophage motility and increased cyto- 
toxicity. 2s-31 OxLDL or its component has also been 
shown to stimulate the expression of several EC pro- 
teins including vascular cell adhesion molecule-1 
(VCAM-1) 32 and other adhesion molecules, 33monocyte 
chemotactic proteins-1 (MCP) 6'34 and granulocyte- 
macrophage colony-stimulating factor (GM-CSF), 
macrophage CSF (M-CSF) and granulocyte CSF (G- 
CSF). 35 Recently it has been demonstrated that OxLDL 
may be directly involved in the atherosclerotic process 
by inhibiting the endothelial cell-dependent release of 
prostacyclin (PGIz), a powerful cycloprotein agent HA 
decrease in PGI2 release might facilitate the adhesion 
of monocytes to the endothelial wall as modifying 
cellular proliferation. 
Smooth muscle cell proliferation plays a key role in 
the development of atherosclerosis and in vessel wall 
thickening. However, the mechanisms responsible for 
SMC are ill-defined. In our study we have dem- 
onstrated that OxLDL increase the proliferation rate 
of aortic SMC. This mitogenic action was partially 
neutralised by antibodies to PDGF AA. These results 
suggest hat the stimulatory effect of OxLDL on the 
growth of SMC is mediated through PDGF AA pro- 
duction. Infact OxLDL stimulated production of PDGF 
AA by SMC in dose-dependent manner. 
PDGF is a major mitogen for connective tissue cells 
in culture and has been shown to be chemotactic 
for SMC. 17 It was originally identified from human 
platelets, but other types of cells were found to be 
able to release PDGF-like molecules, including EC and 
SMC. Pure PDGF was described as a 27- to 31-KD 
glycoprotein that was thought o exist as a dimer of 
two distinct but highly similar polypeptides, which 
were termed A chain and B chain. B6 The principal 
animal model that has been used to study myointimal 
hyperplasia isballoon angioplasty ofnormal rat artery. 
Ferns et al. demonstrated that the development of an 
intimal esion induced by intra-arterial balloon catheter 
was reduced by 40.9% by administration of antibody 
to PDGF. 37 Thus, OxLDL may lead to myointimal 
hyperplasia nd to early atherosclerotic plaque for- 
mation through induction of PDGF production by 
SMC. 
In our study we used high density lipoprotein (HDL) 
as control. Epidemiological data support he protective 
effect of HDL 1~5 in the development of atherosclerosis, 
especially in coronary heart disease. Rubin et al. re- 
ported that transgenic mice with high plasma levels 
of apo A-1 and HDL were protected from the de- 
velopment of fatty streak lesions after exposure to an 
atherogenic diet. 4° Badimon et al. suggested that it may 
be possible not only to inhibit progression, but even 
to reduce established atherosclerosis lesions in cho- 
lesterol-fed rabbits. 41 The "reverse cholesterol trans- 
port" system is currently the most widely accepted 
responsible mechanism of the protective role of HDL in 
the development ofatherosclerosis. 42 Ko et al. proposed 
another mechanism by which HDL could exert a pro- 
tective role in the development of an atherosclerotic 
lesion. They observed infact an inhibitory effect of 
HDL on EGF-induced SMC proliferation in vitro. 43 In 
our study, HDL significantly reduced the production 
of PDGF AA by aortic SMC. The findings of our study 
suggest that the protective role of HDL could be 
exerted through inhibition of PDGF AA release by 
SMC. 
In conclusion, our study demonstrates a link be- 
tween elevated levels of serum LDL and formation of 
the early atherosclerotic plaque which is characterised 
by SMC proliferation and a new protective mechanism 
of HDL on SMC themselves. 
References 
1 STEINBERG D, PARTHASARATHY S, CAREW TE, KHoo JD, WITZTUM 
J. Beyond cholesterol modification of low density lipoprotein 
that increases it  atherogenicity. N Engl J Med 1989; 320: 915-924. 
2 HOLVOET P, COLLEN D. Oxidized lipoproteins inatherosclerosis 
and thrombosis. FASEB J 1994; 8: 1279-1284. 
3 HABERLAND ME, FONG D, CHENG L. Malondialdehyde-altered 
protein occurs in atherome of Watanabe h ritable hyperlipidemic 
rabbits. Science 1988; 241: 215-218. 
4 YLA-HERTTUALA S, PADINSKI W r ROSENFELD ME et al. Evidence 
for the presence ofoxidatively modified low density lipoprotein 
in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 
84: 1086-1095. 
5 STEINBRECHER UP, PARTHASARATHY S, LEAKE DS, WITZTUM JL, 
STEINBERG D. Modification oflow density lipoprotein by endo- 
thelial cells involves lipid peroxidation a d degradation f low 
density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 
81: 3883-3887. 
6 CUSHING SD, BERLINER Ja, VALENTE aJ et al. Minimally modified 
low density lipoprotein duced monocyte chemotactic protein 
1 in human endothelial cells and smooth muscle cells. Proc Natl 
Acad Sci USA 1990; 87: 5134-5138. 
7 LE~R HA, BECKER M, MARKLUND SL et al. Superoxide-dependent 
stimulation ofleukocyte adhesion by oxidafively modified LDL 
in vivo. Arterioscler Thromb 1992; 12: 824-829. 
8 HUGHES DA, TOWNSEND PJ, HASLAM PL. Enhancement of the 
antigen-presenting fu ction of monocytes bycholesterol possible 
relevance toinflammatory mechanisms in extrinsic allergic al- 
veolitis and atherosclerosis. Clin Exp Immunol 1992; 87: 279-286. 
9 NATARAJAN V, SCR1BNER WM, HART CM, PARTHASARATHY S. 
Oxidized low density lipoprotein-mediated activation ofphos- 
pholipase D in smooth muscle cells: a possible role in cell 
Eur J Vasc Endovasc Surg Vol 16, September 1998 
202 A. Cucina et al. 
proliferation and atherogenesis. J Lipid Res 1995; 36: 2005-2016. 
10 WEISSER B, LOCHER R, MENGDEN T, VETTER W. Oxidation of low 
density lipoprotein enhances its potential to increase intracellular 
free calcium concentration i  vascular smooth muscle cells. 
Arterioscler Thromb 1992; 12: 231-236. 
11 THORIN E, HAMILTON C, DOMINICZAK M, REID JL. Chronic 
exposure of cultured endothelial cells to oxidized low density 
lipoprotein abolishes prostacyclin release. Arteriocler Thromb 
1994; 14: 453-459. 
12 GOLDBOURG U, MEDALIE JH. High density lipoprotein cholesterol 
and incidence of coronary heart disease - the Israeli Ischaemic 
Heart Disease Study. Am J Epidemiol 1979; 109: 296-308. 
13 GORDON DJ, PROBSTEIELD JL, GARRISON RJ. High-density lipo- 
protein cholesterol and cardiovascular disease. Four prospective 
American studies. Circulation 1989; 79: 8-15. 
14 GORDON DJ, RIFKIND BM. High-density lipoprotein: the clinical 
implications of recent studies. N EngI J Med 1989; 321: 1311-1316. 
15 STAMEFER MJ, SACKS FM, SALVANI S, WILLET WC, HENNEKENS 
CH. A prospective study of cholesterol apolipoproteins, and the 
risk of myocardial infarction. N Engl J Med 1991; 325: 373-381. 
16 RAINES EW, Ross R. Smooth muscle cells and the pathogenesis 
of the lesions of atherosclerosis. Br Heart ] 1993; 69: $30-$37. 
17 Ross R. The pathogenesis of atherosclerosis: a perspective for 
the 1990s. Nature 1993; 362: 1007-1017. 
18 SJOLUND M, HEDIN U, SEJERSEN T, HELDIN CH, THYBERG J, 
Arterial smooth muscle cells express platelet-derived growth 
factor (PDGF) A chain mRNA, secrete a PDGF-like mitogen, 
and bind exogenous PDGF in a phenotype and growth state 
dependent manner. J Ceil Biol 1988; 106: 403-413. 
19 MAJESKY MW, REIDY MA, BOWEN-POPE DF, HART CE, WILCOX 
JN, SCHWARTZ SM. PDGF ligand and receptor gene expression 
during repair of arterial injury. ] Ceil Biol 1990; 111: 2149-2158. 
20 STERPETTI AV, CUCINA A, CARDILLO B, SANTORO-D'ANGELO L, 
CAVALLARO A. Shear stress modulates the proliferation rate, 
protein synthesis, and mitogenic activity of arterial smooth 
muscle cells. Surgery 1993; 113: 691-699. 
21 PARTHASARATHY S, WIELAND E, STEINBERG D. A role for endo- 
thelial cell lipoxygenase in the oxidative modification of low 
density lipoprotein. Proc Natl Acad Sci USA 1989; 86: 1046-1050. 
22 KRAEMER R, POMERANTZ KB, JOSEPH-SILVERSTEIN J, HAJJAR DP. 
Induction of basic fibroblast growth factor mRNA and protein 
synthesis in smooth muscle cells by cholesteryl ester enrichment 
and 25-hydroxycholesterol. J Biol Chem 1993; 268: 8040-8045. 
23 DUPLAA C, COUFFINHAL T, LABAT Let al. Monocyte adherence 
to endothelial cells in patients with atherosclerosis relationships 
with risk factors. Eur f Clin Invest 1993; 23: 474-479. 
24 CHANG GJ, Woo P, HONDA H]VI et aL Oxidation of LDL to a 
biologicallly active form by derivatives of nitric oxide and nitrite 
in the absence of superoxide. Dependence on pH and oxygen. 
Arterioscler Thromb 1994; 14: 1808-1814. 
25 LEI-IR HA, FREI B, OLOFSSON AM, CAREW TE, ARFORS KE. Pro- 
tection from oxidized LDL-induced leukocyte adhesion to micro- 
vascular and macrovascular endothelium in vivo by vitamin C 
but not by vitamin E. Circulation 1995; 91: 1525-1532. 
26 BERLINER JA, TERRITO MC, SEVANIAN A et al. Minimally modified 
low density lipoprotein stimulates monocyte ndothelial inter- 
actions. J Clin Invest 1990; 85: 1260-1266. 
27 McMURRAY HF, PARTHASARATIIY S, STEINBERG D. Oxidatively 
modified low density lipoprotein is a chemoattractant for human 
T lymphocytes. J CIin Invest 1993; 92: 1004-1008. 
28 LYons TJ, LI W, WELLS-KNECHT MC, JOKE R. Toxicity of mildly 
modified low density lipoproteins to cultured retinal capillary 
endothelial cells and perycytes. Diabetes 1994; 43: 1090-1095. 
29 MARCHANT CE, LAW NS, VAN DER VEEN C, HARDWICK SJ, 
CARPEN KLH, MITCHINSON MJ. Oxidized low density lipoprotein 
is cytotoxic to human monocyte-macrophages: protection with 
lipophilic antioxidants. FEBS Lett 1995; 358: 175-178. 
30 CHISOEM GM, MA G, IRWIN KC et al. 7 beta-hydroperoxycholest- 
5-en-3 beta-ol, a component of human atherosclerotic lesions, is 
the primary cytotoxin of oxidized human low density lipo- 
protein. Proc NatI Acad Sci USA 1994; 91: 11452-11456. 
31 NEGRE-SALVAYRE A, MABILE L, DELCHAMBRE J, SALVAYRE R. 
Alpha-tocopherol, ascorbic acid, and rutin inhibit synergistically 
the copper-promoted LDL oxidation and the cytotoxicity of 
oxidized LDL to cultured endothelial cells. Biol Trace EIera Res 
1995; 47: 81-94. 
32 KHAN BV, PARTHASARATHY SS, ALEXANDER RW, MEDFORD RI~/[. 
Modified low density lipoprotein and its constituents augment 
cytokine-activated vascular cell adhesion molecule-1 gene ex- 
pression in human vascular endothelial cells. J Clin Invest 1995; 
95: 1262-1270. 
33 KUME N, CYBULSKY MI, GIMBRONE MA JR. Lyso- 
phosphatidylcholine, a component of atherogenic lipoprotein, 
induces mononuclear leukocyte adhesion molecules in cultured 
human and rabbit arterial endothelial cells. J Clin Invest 1992; 
90: 1138-1144. 
34 LIAO F, BERLINER JA, MEHRABIAN Met al. Minimally modified 
low density lipoprotein is biologically active in vitro in mice. f 
Clin Invest 1991; 87: 2253-2257. 
35 RAJAVASHISTH TB, ANDALIBI A, TERRITO MC et al. Induction 
of endothelial cell expression of granulocyte and macrophage 
colony-stimulating factors by modified low-density lipoproteins. 
Nature 1990; 344: 254-257. 
36 Ross R, RAINES EW, BOWEN-POPE DE The biology of platelet- 
derived growth factor. Cell 1986; 46: 155-169. 
37 FERNS GAA, RAINES EW, SPRUGEL KH, MOTANI AS, REIDY MA, 
ROSS R. Inhibition of neointimal smooth muscle accumulation 
after angioplasty by an antibody to PDGF. Science 1991; 253: 
1129-1132. 
38 KUKITA H, HIWADA K, KOKUBU T. Serum apoliprotein A-I, A-II 
and B levels and their discriminative values in relatives of 
patients with coronary artery disease. Atherosclerosis 1984; 51: 
261-267. 
39 MILLER NE, HAMMET F~ SALTISSI Sr VAN ZELLER H~ COLTART Jr 
LEWIS B. Relation of angiographically defined coronary artery 
disease to plasma lipoprotein subfractions and apolipoproteins. 
Br Med ] 1981; 282: 1741-1744. 
40 RUBIN EM, KRAUSS RM, SPANGLE EA, VERSTUYVT JG, CLII;T SM. 
Inhibition of early atherogenesis hatransgenic mice by human 
apolipoprotein AI. Nature 1991; 353: 265-267. 
41 BADIMON JJ, BADIMON L, FUSTER V. Regression of atherosclerotic 
lesion by high density lipoprotein plasma fraction in the cho- 
lesterol-fed rabbit. ] Clin hwest 1990; 85: 1234-1241. 
42 FIELDING CJ, FIELDING PE. Molecular physiology of reverse 
cholesterol transport. J Lipid Res 1995; 36: 211-228. 
43 Ko Y, STIEBLER H, WIECZOREK aJ, VETTER H, SACttlNIDIS A. 
High-density lipoprotein reduces epidermal growth factor-in- 
duced DNA synthesis in vascular smooth muscle cells. Athero- 
sclerosis 1993; 99: 253-259. 
Accepted 25 February 1998 
Eur J Vasc Endovasc Surg Vol 16, September 1998 
